Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Development of a non-invasive methylation based predictive model to detect metabolic-associated steatohepatitis in type 2 diabetic patients

EF 2025-26

Résumé
The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing concern, particularly among individuals with type 2 diabetes (T2D), who have a high risk of silently developing its aggressive form, metabolic dysfunction–associated steatohepatitis (MASH). Currently, liver biopsy remains the gold standard for diagnosing MASH, but its invasive nature carries risks such as bleeding and infection, limiting its feasibility for widespread screening. Given these challenges, there is a need for a non-invasive diagnostic tool that can accurately identify patients at risk. Recent studies in the diabetic population have found that DNA methylation patterns in several tissues are associated with metabolic traits such as high blood glucose, obesity, and diabetes. These findings suggest that methylation-based biomarkers could be used to create a novel screening approach. My proposed research aims to develop a machine-learning model that integrates methylation data and clinical variables to screen for MASH in patients with T2D. We will profile blood samples from diabetic patients with and without MASH to generate DNA methylation profiles to look for differences between the two groups. I will perform standard quality checks and clean the data to identify the top differentially methylated loci (DMLs) between the two groups. I will then test multiple machine-learning models to distinguish MASH cases from non-MASH controls. By integrating bioinformatics with clinical insights, this approach aims to improve detection and risk stratification for MASH in individuals with T2D. The developed model has the potential to facilitate earlier intervention, enabling more frequent monitoring and personalized treatment strategies for at-risk patients.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573012
Name
Ray Ankit
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a non-invasive methylation based predictive model to detect metabolic-associated steatohepatitis in type 2 diabetic patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cell-Free Dna Methylation; Machine Learning; Metabolic Dysfunction-Associated Steatohepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes
Abstract
The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing concern, particularly among individuals with type 2 diabetes (T2D), who have a high risk of silently developing its aggressive form, metabolic dysfunction–associated steatohepatitis (MASH). Currently, liver biopsy remains the gold standard for diagnosing MASH, but its invasive nature carries risks such as bleeding and infection, limiting its feasibility for widespread screening. Given these challenges, there is a need for a non-invasive diagnostic tool that can accurately identify patients at risk. Recent studies in the diabetic population have found that DNA methylation patterns in several tissues are associated with metabolic traits such as high blood glucose, obesity, and diabetes. These findings suggest that methylation-based biomarkers could be used to create a novel screening approach. My proposed research aims to develop a machine-learning model that integrates methylation data and clinical variables to screen for MASH in patients with T2D. We will profile blood samples from diabetic patients with and without MASH to generate DNA methylation profiles to look for differences between the two groups. I will perform standard quality checks and clean the data to identify the top differentially methylated loci (DMLs) between the two groups. I will then test multiple machine-learning models to distinguish MASH cases from non-MASH controls. By integrating bioinformatics with clinical insights, this approach aims to improve detection and risk stratification for MASH in individuals with T2D. The developed model has the potential to facilitate earlier intervention, enabling more frequent monitoring and personalized treatment strategies for at-risk patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ray, Ankit
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~